Evolent Health (EVH) Gains from Investment Securities (2016 - 2025)

Evolent Health's Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $4.7 million for Q4 2025.

• On a quarterly basis, Gains from Investment Securities rose 210.9% year-over-year to $4.7 million in Q4 2025; TTM through Mar 2026 was $6.8 million, a 258.29% increase from a year earlier, with the FY2025 full-year figure at $6.5 million, up 32.33% from the prior year.
• Gains from Investment Securities improved to $4.7 million in Q4 2025 per EVH's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $14.1 million in Q4 2021 and bottomed at -$17.7 million in Q4 2022.
• The 5-year median for Gains from Investment Securities is $500000.0 (2022), against an average of $1.1 million.
• Biggest YoY gain for Gains from Investment Securities was 1123.23% in 2022; the steepest drop was 5544.44% in 2022.
• Year by year, Gains from Investment Securities stood at $14.1 million in 2021, then plunged by 225.53% to -$17.7 million in 2022, then soared by 133.54% to $5.9 million in 2023, then plunged by 170.74% to -$4.2 million in 2024, then jumped by 210.9% to $4.7 million in 2025.
• Per Business Quant, the three latest EVH Gains from Investment Securities figures stand at $4.7 million (Q4 2025), -$1.1 million (Q3 2025), and $3.2 million (Q2 2025).